Jane Street’s Summit Therapeutics SMMT Stock Holding History

Jane Street’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.73M	Sell	196,600 -83,400	-30%	-$1.35M	﹤0.01%	3974
2025 Q4	$4.9M	Sell	280,000 -129,700	-32%	-$2.44M	﹤0.01%	3252
2025 Q3	$8.46M	Buy	409,700 +97,400	+31%	+$2.36M	﹤0.01%	2634
2025 Q2	$6.65M	Sell	312,300 -193,800	-38%	-$4.42M	﹤0.01%	2642
2025 Q1	$9.76M	Buy	506,100 +115,400	+30%	+$2.32M	﹤0.01%	2017
2024 Q4	$6.97M	Sell	390,700 -59,800	-13%	-$1.16M	﹤0.01%	2262
2024 Q3	$9.87M	Buy	450,500 +431,300	+2,246%	+$6.03M	﹤0.01%	1926
2024 Q2	$150K	Buy	+19,200	New	+$104K	﹤0.01%	8572
2023 Q2	–	Sell	-25,300	Closed	-$44.3K	–	9508
2023 Q1	$44.3K	Sell	25,300 -12,300	-33%	-$33.5K	﹤0.01%	8483
2022 Q4	$160K	Buy	+37,600	New	+$68.4K	﹤0.01%	7829

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jane Street's SMMT Position: Q3 2025 in Review

Jane Street sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 249,710 shares — an estimated $6.06M sold.

Jane Street first reported a position in SMMT in Q4 2021 and held it in 12 quarters. The position peaked at $7.69M in Q3 2024. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Jane Street reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Jane Street sold 249,710 Summit Therapeutics shares in Q3 2025, an estimated $6.06M.
Jane Street first reported a position in Summit Therapeutics in Q4 2021 and held it in 12 quarters.
Jane Street's Summit Therapeutics position peaked at $7.69M in Q3 2024.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.